“Pharmaceutical prices have been unchecked for far too long,” says Mendoza. “We’ve seen that consistently for more than a decade, that pharmaceutical companies, when they have a monopoly, will raise the price so they can show profits to their shareholders and keep their investors happy.”
“This is just yet another tactic used by large pharmaceutical manufacturers to try to hold on to profits without innovating anything new for patients.”
